Rep. Doris Matsui Doris Okada MatsuiDemocratic lawmaker calls telehealth expansion the 'silver lining' of pandemic The Hill's 12:30 Report: Delegates stage state-centric videos for the roll call Overnight Health Care: Obama leans into Trump criticism on coronavirus | CDC gives 3-month window for COVID-19 immunity MORE (D-Calif.) and Rep. Brett Guthrie Steven (Brett) Brett GuthrieIgnore the misinformation: The FDA will ensure the safety of any COVID-19 vaccine House Republicans introduce legislation to give states 0 million for elections Hillicon Valley: Tech giants poised to weather coronavirus damage | Record Facebook-FTC deal approved | Bipartisan 5G bill introduced MORE (R-Ky.) put forward their ideas for improving Medicare Part D during an event on Tuesday at a time when seniors are facing rising out-of-pocket costs and fewer options for affordable medications.

“My fix is that you have to look at the whole thing, and this is a shared responsibility," Matsui told moderator Steve Clemons at The Hill's "Cost, Quality and Care: The Medicare Equation" event, sponsored by Astellas Pharma US.

ADVERTISEMENT

"The federal government can’t just offload it on to the beneficiaries, or to the plans to the manufacturers. We are all in this together," she continued.

Matsui, who sits on the House Energy and Commerce Committee, pointed to the issue surrounding the rising cost of single-source drugs, which are brand name drugs that do not have a generic alternative.

"The market can only go a certain distance. For instance, with high-cost drugs, for particularly those particularly terribly ill, many of them [drugs] are single-source," she said. "In many cases, the beneficiary pays a certain amount, and then the plans are responsible. So we really feel that something there is wrong in a sense there's no competition there, so it only goes a certain length of time."

As part of his path forward on the program, Guthrie suggested moving forward on the issue of generic drugs as a part of the Medicare program.

“A lot of it is how do we get generics adopted quicker and how do we add generics to the market place quicker," Guthrie, who also is on the Energy and Commerce Committee, told The Hill's editor-in-chief Bob Cusack Robert (Bob) CusackThe Hill's Campaign Report: Biden asks if public can trust vaccine from Trump ahead of Election Day | Oklahoma health officials raised red flags before Trump rally Shakespeare Theatre Company goes virtual for 'Will on the Hill...or Won't They?' The Hill's 12:30 Report - Presented by Facebook - Big 10 votes to resume football season MORE in a separate interview.

The congressman struck a bipartisan tone when asked about any potential agreement, saying we could see progress as soon as this fall.

"This fall would probably be the right time to get it done by," he said. "You can put a group together and say let's hammer out some true drug pricing, transparency, drug pricing strategies."

"We can really sit down and hammer out I think a deal that the president would sign that would make life better for people in the country," he added.

President Trump Donald John TrumpSteele Dossier sub-source was subject of FBI counterintelligence probe Pelosi slams Trump executive order on pre-existing conditions: It 'isn't worth the paper it's signed on' Trump 'no longer angry' at Romney because of Supreme Court stance MORE has long bemoaned rising drug costs in the pharmaceutical industry and has moved recently to lower prices.

Earlier this month, Department of Health and Human Services sent the White House a proposal, aiming to lower certain drug prices in Medicare by connecting them to the lower prices paid in other countries, known as the international pricing index.

The idea is vehemently opposed by the pharmaceutical industry and is a departure from the GOP's free-market dogma.

It is unclear what kind of changes the White House will make to the proposal, and how long the reviewal process will take.